Cytomegalovirus Control in Critical Care

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions
Critical Illness
Interventions
DRUG

Valaciclovir/Aciclovir

2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.

DRUG

Valganciclovir/Ganciclovir

450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction

Trial Locations (1)

B15 2WB

University Hospitals Birmingham NHS Foundation Trust, Birmingham

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University Hospital Birmingham NHS Foundation Trust

OTHER

NCT01503918 - Cytomegalovirus Control in Critical Care | Biotech Hunter | Biotech Hunter